Metadata

Name Psoriasis
Type Disease or Syndrome
Group Psoriasis
Data Sources
Clinical Terminologies Read Version 2
Codelists
Valid Event Data Range 01/01/1994 - 31/12/2009
Sex Female
Male
Authors Rosa Parisi, Martin K Rutter, Mark Lunt, Helen S Young, Deborah P M Symmons, Christopher E M Griffiths, Darren M Ashcroft
Agreement Date 9 Apr 2015
Version (UUID) Revision 1 (3CrnLA26CnYaWik6DfCfdt)

Primary Care

code coding_system description entity list_name upload_date
M16..00 Read Psoriasis and similar disorders diagnostic 696 - res66: psoriasis 2018-04-17
M161.00 Read Other psoriasis diagnostic 696 - res66: psoriasis 2018-04-17
M161000 Read Psoriasis unspecified diagnostic 696 - res66: psoriasis 2018-04-17
M161100 Read Psoriasis annularis diagnostic 696 - res66: psoriasis 2018-04-17
M161200 Read Psoriasis circinata diagnostic 696 - res66: psoriasis 2018-04-17
M161300 Read Psoriasis diffusa diagnostic 696 - res66: psoriasis 2018-04-17
M161400 Read Psoriasis discoidea diagnostic 696 - res66: psoriasis 2018-04-17
M161500 Read Psoriasis geographica diagnostic 696 - res66: psoriasis 2018-04-17
M161600 Read Guttate psoriasis diagnostic 696 - res66: psoriasis 2018-04-17
M161700 Read Psoriasis gyrata diagnostic 696 - res66: psoriasis 2018-04-17
M161800 Read Psoriasis inveterata diagnostic 696 - res66: psoriasis 2018-04-17
M161900 Read Psoriasis ostracea diagnostic 696 - res66: psoriasis 2018-04-17
M161A00 Read Psoriasis palmaris diagnostic 696 - res66: psoriasis 2018-04-17
M161B00 Read Psoriasis plantaris diagnostic 696 - res66: psoriasis 2018-04-17
M161C00 Read Psoriasis punctata diagnostic 696 - res66: psoriasis 2018-04-17
M161E00 Read Psoriasis universalis diagnostic 696 - res66: psoriasis 2018-04-17
M161F00 Read Psoriasis vulgaris diagnostic 696 - res66: psoriasis 2018-04-17
M161F11 Read Chronic large plaque psoriasis diagnostic 696 - res66: psoriasis 2018-04-17
M161H00 Read Erythrodermic psoriasis diagnostic 696 - res66: psoriasis 2018-04-17
M161z00 Read Psoriasis NOS diagnostic 696 - res66: psoriasis 2018-04-17
M16y.00 Read Other psoriasis and similar disorders diagnostic 696 - res66: psoriasis 2018-04-17
M16y000 Read Scalp psoriasis diagnostic 696 - res66: psoriasis 2018-04-17
M16z.00 Read Psoriasis and similar disorders NOS diagnostic 696 - res66: psoriasis 2018-04-17
Myu3000 Read [X]Other psoriasis diagnostic 696 - res66: psoriasis 2018-04-17

Implementation

The study population included patients with a first diagnosis of psoriasis between 1 January 1994 and 31 December 2009, who were 20 years or older at the time of the diagnosis. A comparison group of up to 5 controls per psoriasis patient was selected. Patients from both cohorts did not have any history of CVD or diabetes before the index date (first diagnosis of psoriasis) or corresponding consulting date and, in order to capture incident not prevalent cases of psoriasis or major CV events, all patients had to have at least 2 years prior registration within their general practice before entry into the study cohort. The control group consisted of patients who never received a diagnostic code for psoriasis. Controls were matched to psoriasis patients by age, gender, and general practice. We assigned control patients the same index date as the patients with psoriasis to whom they were matched. Person-time under observation for each patient was calculated from the corresponding index date up to the end of the study, which was the earliest date of the occurrence of a major CV event (MI, ACS, unstable angina, or stroke), transfer out of the practice, death date, end of follow-up (31 December 2011) or when the practice was no longer up to research data quality standards set by CPRD. Patient consent was not required; all patient data contained in CPRD is anonymised.

Patients with psoriasis were included if they had their first diagnostic code for psoriasis during 1 January 1994–31 December 2009 and received a recognized treatment for psoriasis (emollients, topical treatment, phototherapy, systemic therapy, or biologics (CG153 Psoriasis: NICE guideline; Samarasekera and Smith, 2014)). Patients were classified as having severe psoriasis once they had received a systemic treatment (acitretin, etretinate, ciclosporin, hydroxycarbamide, methotrexate, and fumaric acid), phototherapy, or a biologic therapy (etanercept, adalimumab, infliximab, ustekinumab, and efalizumab); alternatively they were classified as mild psoriasis.

Publications

Rosa Parisi, Martin K Rutter, Mark Lunt, Helen S. Young, Deborah P M Symmons, Christopher E M Griffiths, Darren M. Ashcroft, "Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink". Journal of Investigative Dermatology, 135(9), 2189-2197, 2015.